Marketing Audit
Marketing Audit: MitoRx Therapeutics
55/100 (Grade: C)
Prepared by Growth Experts — March 2025
Marketing Audit
Prepared by Growth Experts — March 2025
MitoRx Therapeutics has a strong scientific story and credible team — a clear differentiator in the obesity space (fat loss without lean mass loss vs GLP-1 muscle loss). The site passes the basics: it conveys credibility, explains the mechanism, and lists team credentials. But the marketing score of 55/100 (Grade: C) reflects significant gaps that limit BD conversion and discoverability.
Biggest strength: Scientific credibility and differentiation. The mtH2SD platform, trans-sulfuration mechanism, peer-reviewed work, and Prof Whiteman's 180+ publications create a defensible story. The "lean mass preservation" angle is a genuine differentiator vs Ozempic/Wegovy.
Biggest gap: Conversion design. Primary CTAs are mailto links, there is no lead qualification, and no dedicated path for BD or investor enquiries.
Top 3 actions: (1) Replace mailto CTAs with a contact form and lead qualification; (2) Fix sitemap and add meta descriptions; (3) Lead with the GLP-1 contrast. Est. pipeline impact: £5,000–£15,000/month in qualified BD opportunities.
Strengths: Strong scientific credibility, experienced team (15+ bios, 5 approved medicines co-discovered), conference presence (ADA, EASD, ECO 2025), differentiated positioning.
Gaps: Differentiation underspecified; weak CTAs; no audience segmentation; limited proof depth.
Recommendations: Lead with GLP-1 contrast; add BD-specific hero line; replace mailto with form; segment CTAs by audience.
Strengths: Trust signals; low-friction form; clear structure; no pricing page (correct for B2B pharma.
Gaps: Mailto as primary CTA; no lead qualification; generic CTAs; no dedicated path for partners vs investors.
Recommendations: Replace mailto CTAs; add lead qualification; create Partnering page; differentiate CTAs by intent.
Strengths: Clean URL structure; robots.txt; strong homepage content; internal linking; HTTPS.
Gaps: Sitemap returns 500; missing meta descriptions; generic page titles; no structured data.
Recommendations: Fix sitemap; add unique meta descriptions; improve page titles; implement Organisation and Article schema.
Strengths: Clear differentiation; sub-category creation; mechanism-based story; thought leadership.
Gaps: No competitor comparison content; weak external validation; limited partnership proof.
Recommendations: Create comparison content; lead with lean mass preservation; pursue analyst recognition; add partnership proof.
Strengths: Strong team credentials; SAB; conference presence; clear "Work with us" positioning.
Gaps: No content hub; no lead magnets; no partner logos or case studies.
Recommendations: Create content hub; introduce lead magnet; add partner logos and proof.
Strengths: Clear business model and partnership intent; conference presence; LinkedIn presence.
Gaps: Inbound-only lead gen; no outbound; no paid demand generation; narrow channel mix.
Recommendations: Add BD outreach process; build partner/investor email programme; test paid LinkedIn; define channel strategy.
| Factor | MitoRx | Novo Nordisk (Ozempic/Wegovy) | Eli Lilly (Zepbound) |
|---|---|---|---|
| Headline clarity | 7/10 | 9/10 | 8/10 |
| Differentiation | 8/10 | 5/10 | 6/10 |
| Trust signals | 5/10 | 9/10 | 8/10 |
| Competitor awareness | 3/10 | 6/10 | 6/10 |
| Category ownership | 8/10 | 7/10 | 6/10 |
| BD/partnership appeal | 7/10 | N/A | N/A |
| Recommendation | Est. Monthly Impact | Confidence | Timeline |
|---|---|---|---|
| Replace mailto + lead qualification | £2,000–£5,000 | Medium | 1 week |
| Fix sitemap + meta descriptions | £500–£1,500 | Medium | 1 week |
| Lead with GLP-1 contrast | £1,000–£3,000 | Medium | 1 week |
| Dedicated Partnering page | £2,000–£5,000 | Medium | 2–4 weeks |
| Comparison content (vs GLP-1s) | £1,500–£4,000 | Medium | 2–4 weeks |
| Content hub + lead magnet | £2,000–£6,000 | Low | 4–8 weeks |
| Structured BD outreach | £3,000–£10,000 | Low | 4–8 weeks |
| Total Potential | £12,000–£34,000/mo |
For a pre-revenue biotech, "pipeline" is qualified BD opportunities and investor interest. Impact is qualitative (partner quality, deal velocity) as well as quantitative.
MitoRx's marketing is strongest in science and credibility; the gaps are in conversion design, discoverability, and systematic demand generation. Growth Experts can help with website CRO, content marketing, competitive positioning, and demand generation. A Discovery call would clarify scope and fit.
Book a discovery callPrepared by Growth Experts — Strategic B2B Growth Partner